



Inventors: Ruoslahti et al.  
Serial No.: 09/765,086  
Filed: January 17, 2001

#### APPENDIX A

##### Amendments to the specification:

The second full paragraph on page 77.

A chimeric peptide of the invention is selectively delivered to the prostate due to the selective homing activity of the prostate-homing peptide portion. A variety of prostate-homing peptides are useful in the invention, including SMSIARL (SEQ ID NO: 207) and VSFLEYR (SEQ ID NO: 222), which were identified by injection of an X<sub>1</sub> library into mice (Table [7] 5) and subsequent *in vivo* panning as described in U.S. Patent No. 5,622,699. The prostate-homing peptides SMSIARL (SEQ ID NO: 21) and VSFLEYR (SEQ ID NO: 22) exhibited a 34-fold and 17-fold enrichment, respectively, in prostate as compared to brain.

##### Amendments to the claims:

8. (Amended) A method of directing an antimicrobial peptide *in vivo* to [a] prostate tissue [cancer], comprising administering a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,  
said chimeric peptide exhibiting selective toxicity to prostate tissue, and  
said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing peptide [the chimeric peptide of claim 1].

Inventors: Ruoslahti et al.  
Serial No.: 09/765,086  
Filed: January 17, 2001

13. (Amended) A method of selectively inducing apoptosis in prostate tissue in vivo [selective toxicity in vivo in a prostate cancer], comprising administering to a subject a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,  
said chimeric peptide exhibiting selective toxicity to prostate tissue, and  
said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing peptide [the chimeric peptide of claim 1 to a subject having prostate cancer].